Open an account

TG Therapeutics

TGTX · NASDAQ

$54.53+$1.23 (+2.31%)TodayMarket closed ·
Prev close $53.30

About TGTX

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. The company is headquartered in Morrisville, North Carolina and currently employs 399 full-time employees. Its products include Ublituximab IV (anti-CD20 mAb), Ublituximab IV Simplified Dosing Schedule, Ublituximab Subcutaneous (anti-CD20 mAb), and Azer-cel. The company is engaged in late-stage clinical development of BRIUMVI. BRIUMVI is an anti-CD20 monoclonal antibody that can be administered to adults with relapsing forms of multiple sclerosis (RMS) in a one-hour infusion every 24 weeks, following the starting dose. The company is used for treatment of adults with clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease. The firm is also engaged in ULTIMATE I & II Trials Evaluating Single Agent Ublituximab in RMS. Its ENHANCE Phase 3b Trial is an ongoing, multi-center, open-label study designed to evaluate alternative dosing regimens for BRIUMVI in patients with RMS.

Employees
399
Headquarters
Morrisville, North Carolina
Listed
Dec 14, 1995
Sector
Health Care
Industry
Biotechnology
Website
tgtherapeutics.com

TGTX key statistics

Market cap
8.16B
Price-earnings ratio
19.38
Dividend yield
—
Average volume
1.65M
Volume
1.06M
Open price
$53.36
High today
$55.32
Low today
$53.08
52 Week high
$59.30
52 Week low
$26.76

TG Therapeutics (TGTX) at a glance

TG Therapeutics (TGTX) last traded at $54.53, with a market cap of 8.16B and a price-to-earnings ratio of 19.38.

Today the stock has traded between $53.08 and $55.32. The current price is 2.7% above the day's low and 1.4% below its high.

Volume so far is 1.06M shares, below the average of 1.65M shares a day.

Over the past year TG Therapeutics has ranged from $26.76 to $59.30, and now sits 85% of the way up that range.

TG Therapeutics met or beat analyst EPS estimates in 1 of the last 8 quarters. In Q2 FY26 it reported $0.05 per share against an estimate of $0.3443.

The average analyst price target is $70.72, 29.7% above the current price, from 6 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

67%of 6 analyst ratings say Buy
  • Buy66.7%
  • Hold16.7%
  • Sell16.7%
Price target · 9 analystsAvg $70.72
Low
$21.21
Now
$54.53
High
$90.30

TGTX earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 1 of the last 8 quarters, by 77.1% on average.

  1. Q3 FY24: reported $0.02 per share against an estimate of $0.0301
  2. Q4 FY24: reported $0.15 per share against an estimate of $0.0847
  3. Q1 FY25: reported $0.03 per share against an estimate of $0.1855
  4. Q2 FY25: reported $0.17 per share against an estimate of $0.2215
  5. Q3 FY25: reported $0.16 per share against an estimate of $0.2244
  6. Q4 FY25: reported $0.14 per share against an estimate of $0.3583
  7. Q1 FY26: reported $0.18 per share against an estimate of $0.3005
  8. Q2 FY26: reported $0.05 per share against an estimate of $0.3443

TGTX news

  • Press releaseBusiness Wire

    TG Therapeutics Announces Publication of Five-Year Comparative Analysis of BRIUMVI Versus Ocrelizumab and Ofatumumab in Relapsing Multiple Sclerosis

  • Press releaseBusiness Wire

    TG Therapeutics Announces Schedule of Data Presentations at MSToronto2026

  • Press releasePRNewswire

    Kuehn Law Encourages Investors of TG Therapeutics, Inc. to Contact Law Firm

  • Chandrima Sanyal

    Biotech ETF XBI Hits an Interest Rate Wall as 40+ Catalysts Approach

  • Press releaseGlobe Newswire

    Historic First in MS Treatment Could Reshape a Multibillion-Dollar Therapeutics Market

  • Press releaseBusiness Wire

    Precision BioSciences Reports Second Quarter 2026 Financial Results and Provides Business Update

  • Press releasePRNewswire

    Kuehn Law Encourages Investors of TG Therapeutics, Inc. to Contact Law Firm

  • Press releaseGlobe Newswire

    The Quest to Repair What Multiple Sclerosis Takes Away

Similar companies

Companies in the same industry as TG Therapeutics

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.